Updated:
Quebec Consortium for Drug Discovery
The Quebec Consortium for Drug Discovery was formed with provincial support from Quebec and Ontario to bridge lab research and clinical investment.
Quebec Consortium for Drug Discovery
The Quebec Consortium for Drug Discovery was formed with provincial support from Quebec and Ontario to bridge lab research and clinical investment. It is not a single family office but a consortium that coordinates government grants, academic institutions, and private investors to de-risk drug discovery projects. The consortium funds a portfolio of small-molecule and biologic candidates, typically at preclinical through Phase I stages. Disease areas include oncology, rare genetic disorders, and metabolic conditions. It operates across Quebec and Ontario, with anchor collaborations at universities in Montreal and Toronto. Named portfolio companies include spinouts from McGill University and the Université de Montréal. Deployment and staffing figures are not public. The consortium maintains a lean operational team, supplemented by academic principal investigators and industry partners. No philanthropic foundation or separate investment vehicle has been identified as affiliated. Recent activity is not documented in public sources. The consortium represents a structural experiment in regional drug development, blending public research funding with private sector governance. Its governance model involves a board composed of academic, government, and industry representatives — distinct from typical venture capital or corporate R&D structures.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Toronto, Ontario, Canada
Sector focus
Frequently asked questions
Who runs investment decisions at the Quebec Consortium for Drug Discovery?
The consortium is governed by a board representing academic institutions, provincial government bodies, and industry partners. Named investment executives have not been publicly disclosed. Operational decisions likely rest with a managing director or executive committee, though names are not available.
How does the consortium source proprietary deal flow?
Deal flow originates primarily from academic institutions in Quebec and Ontario, including McGill University and Université de Montréal. The consortium screens preclinical projects from these universities and provides funding to advance candidates toward clinical proof-of-concept. Proprietary access is driven by geographic proximity and academic partnerships.
Is this structured as a single family office or does it operate more like a venture firm?
The Quebec Consortium for Drug Discovery is not a family office. It is structured as a public-private partnership or consortium, blending government grants, university contributions, and private capital. It functions similarly to a venture philanthropy or a translational research initiative, not a traditional investment manager.
What investment stages does the consortium typically target?
The consortium focuses on early-stage drug development — preclinical candidates through Phase I clinical trials. It does not typically fund later-stage clinical development or commercial launches. The goal is to de-risk assets to attract follow-on investment from pharmaceutical companies or larger venture capital.
Which disease areas does the consortium explicitly prioritize?
The consortium targets oncology, rare genetic disorders, and metabolic conditions. It focuses on small molecules and biologics. Specific disease subareas have not been publicly detailed, but the emphasis is on unmet medical needs and assets emanating from Quebec's academic research ecosystem.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: